Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedFeb 15, 2026
DataAggregated Company Financials
Companies152
  • 7D-2.9%
  • 3M-6.8%
  • 1Y-10.7%
  • YTD-2.9%

Over the last 7 days, the Healthcare industry has dropped 2.9%, driven by a pullback from Camurus of 19%. However, the industry is down 11% over the past year. Earnings are forecast to grow by 26% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 15 Feb 2026SEK 565.4bSEK 230.7b-SEK 1,735,172,894.8930.8x-325.8x2.5x
Tue, 13 Jan 2026SEK 591.8bSEK 230.2bSEK 3.7b41x161.3x2.6x
Thu, 11 Dec 2025SEK 584.0bSEK 230.5bSEK 3.5b41.4x164.8x2.5x
Sat, 08 Nov 2025SEK 587.5bSEK 229.8bSEK 2.9b44.7x202.5x2.6x
Mon, 06 Oct 2025SEK 614.2bSEK 227.1bSEK 6.6b43.2x93x2.7x
Wed, 03 Sep 2025SEK 610.1bSEK 227.2bSEK 6.6b44.6x92.6x2.7x
Fri, 01 Aug 2025SEK 626.0bSEK 226.8bSEK 6.5b51.6x95.8x2.8x
Sun, 29 Jun 2025SEK 616.8bSEK 226.8bSEK 5.9b44.9x105.1x2.7x
Tue, 27 May 2025SEK 597.5bSEK 226.0bSEK 6.6b38.1x90.8x2.6x
Thu, 24 Apr 2025SEK 563.8bSEK 222.2bSEK 4.9b38.5x115.2x2.5x
Sat, 22 Mar 2025SEK 556.7bSEK 206.2bSEK 5.0b36.7x110.3x2.7x
Mon, 17 Feb 2025SEK 594.9bSEK 206.5bSEK 2.5b41.7x237.8x2.9x
Wed, 15 Jan 2025SEK 572.2bSEK 201.6b-SEK 2,648,231,775.5139x-216.1x2.8x
Fri, 13 Dec 2024SEK 572.6bSEK 202.8b-SEK 2,465,110,847.0638.3x-232.3x2.8x
Sun, 10 Nov 2024SEK 528.0bSEK 200.2b-SEK 2,454,224,230.9538.6x-215.2x2.6x
Tue, 08 Oct 2024SEK 603.4bSEK 200.1b-SEK 2,782,864,383.9938.7x-216.8x3x
Thu, 05 Sep 2024SEK 606.1bSEK 200.1b-SEK 2,809,341,520.0139x-215.7x3x
Sat, 03 Aug 2024SEK 569.5bSEK 199.6b-SEK 2,762,712,499.7440.4x-206.1x2.9x
Mon, 01 Jul 2024SEK 562.0bSEK 195.7b-SEK 3,202,643,667.9236.8x-175.5x2.9x
Wed, 29 May 2024SEK 556.4bSEK 195.9b-SEK 2,792,392,543.2436.3x-199.2x2.8x
Fri, 26 Apr 2024SEK 547.0bSEK 195.2b-SEK 3,609,418,549.8644.5x-151.6x2.8x
Sun, 24 Mar 2024SEK 519.8bSEK 192.7b-SEK 3,668,825,382.9843.3x-141.7x2.7x
Tue, 20 Feb 2024SEK 517.5bSEK 191.7b-SEK 4,105,248,032.6349x-126.1x2.7x
Thu, 18 Jan 2024SEK 546.4bSEK 191.7b-SEK 968,025,477.0047.7x-564.5x2.9x
Sat, 16 Dec 2023SEK 543.4bSEK 191.4b-SEK 942,084,132.0050.3x-576.8x2.8x
Mon, 13 Nov 2023SEK 470.7bSEK 190.3b-SEK 1,054,239,686.0049.4x-446.5x2.5x
Wed, 11 Oct 2023SEK 450.7bSEK 184.9b-SEK 2,029,425,074.0034.2x-222.1x2.4x
Fri, 08 Sep 2023SEK 454.7bSEK 185.7b-SEK 2,025,575,303.0036.2x-224.5x2.4x
Sun, 06 Aug 2023SEK 473.1bSEK 183.9b-SEK 1,034,178,130.0039.9x-457.5x2.6x
Tue, 04 Jul 2023SEK 474.9bSEK 179.3b-SEK 795,617,474.0044.8x-596.9x2.6x
Thu, 01 Jun 2023SEK 506.4bSEK 178.8b-SEK 545,224,135.0042.7x-928.7x2.8x
Sat, 29 Apr 2023SEK 518.2bSEK 175.8b-SEK 792,830,499.0035.3x-653.6x2.9x
Mon, 27 Mar 2023SEK 482.3bSEK 172.4b-SEK 1,417,086,752.0035.3x-340.4x2.8x
Wed, 22 Feb 2023SEK 497.2bSEK 170.0b-SEK 579,935,044.0038x-857.3x2.9x
Price to Earnings Ratio

-857.3x


Total Market Cap: SEK 497.2bTotal Earnings: -SEK 579,935,044.00Total Revenue: SEK 170.0bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -172.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.5x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 11% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market-1.01%
Healthcare-2.91%
Biotech2.57%
Medical Equipment-0.54%
Healthcare Services-6.67%
Life Sciences-9.69%
Healthtech-10.17%
Pharma-14.96%
Industry PE
  • Investors are most optimistic about the Medical Equipment industry even though it's trading below its 3-year average PE ratio of 98.2x.
    • Analysts are expecting annual earnings growth of 21.1%, which is higher than its past year's earnings decline of 44.3% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 36% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 407.603.0%
+SEK 4.1b		31.7%PE294.8x
BIOA B BioArcticSEK 322.205.0%
+SEK 1.4b		51.7%PE28.6x
MCOV B MedicoverSEK 209.002.7%
+SEK 830.4m		1.0%PE38.5x
VIMIAN Vimian GroupSEK 27.844.6%
+SEK 645.7m		-39.4%PE44.5x
BONEX Bonesupport HoldingSEK 180.805.4%
+SEK 612.5m		-45.1%PE78.4x

Latest News

STIL
SEK 181.00
Stille
7D
20.7%
1Y
-28.2%

Stille AB Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Feb 15
Stille AB Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
AMBEA
SEK 115.90
Ambea
7D
-17.2%
1Y
7.5%

Ambea (STO:AMBEA) Is Increasing Its Dividend To SEK2.65

Feb 15
Ambea (STO:AMBEA) Is Increasing Its Dividend To SEK2.65
BIOG B
SEK 103.70
BioGaia
7D
-5.0%
1Y
-19.2%
CAMX
SEK 553.50
Camurus
7D
-19.4%
1Y
-6.8%
MCAP
SEK 480.00
MedCap
7D
-11.8%
1Y
20.9%
MCOV B
SEK 209.00
Medicover
7D
2.7%
1Y
1.0%
VIMIAN
SEK 27.84
Vimian Group
7D
4.6%
1Y
-39.4%
ASKER
SEK 65.08
Asker Healthcare Group
7D
-15.8%
1Y
n/a
BONEX
SEK 180.80
Bonesupport Holding
7D
5.4%
1Y
-45.1%

Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?

Feb 12
Is There An Opportunity With Bonesupport Holding AB (publ)'s (STO:BONEX) 43% Undervaluation?
ALIF B
SEK 138.10
AddLife
7D
-9.1%
1Y
-21.1%

Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings

Feb 12
Investors Shouldn't Be Too Comfortable With AddLife's (STO:ALIF B) Earnings
GETI B
SEK 201.20
Getinge
7D
-1.3%
1Y
-5.2%

GETI B: Higher P/E Expectations Will Outrun Softer Margins And Dividend Uplift

Analysts have adjusted their price target on Getinge from SEK165.00 to about SEK171.00, reflecting updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E expectations. What's in the News Getinge AB (publ) has a proposed dividend of SEK 4.75 per share, compared with SEK 4.60 per share previously, subject to approval (Key Developments).
BIOA B
SEK 322.20
BioArctic
7D
5.0%
1Y
51.7%
SOBI
SEK 407.60
Swedish Orphan Biovitrum
7D
3.0%
1Y
31.7%
MVIR
SEK 1.18
Medivir
7D
110.4%
1Y
-50.3%
SECT B
SEK 181.70
Sectra
7D
-12.9%
1Y
-29.3%

SECT B: Cloud Contracts And Pathology Expansion Will Support Future Upside Potential

Analysts have reaffirmed their price target on Sectra at SEK 245.00, with only marginal tweaks to underlying model inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, supporting an unchanged view of fair value. What's in the News TUM Klinikum in Germany is expanding its Sectra enterprise imaging setup with pathology and ophthalmology modules under a five year contract covering up to 300,000 examinations per year, aimed at higher efficiency and closer collaboration across departments (Client announcement).
HNSA
SEK 40.00
Hansa Biopharma
7D
10.4%
1Y
72.4%

HNSA: US Kidney Transplant Approval Timing Will Drive Downside Risk

Analysts have nudged their price target for Hansa Biopharma to SEK 69, reflecting updated assumptions on growth, profitability and valuation multiples, supported by views that imlifidase underpins a more de-risked commercial profile across kidney transplantation, autoimmune disease and gene therapy. Analyst Commentary Recent Street research frames Hansa Biopharma as a company with a clearly defined lead asset and a focused commercial plan across kidney transplantation, autoimmune disease and gene therapy.